Sourcing Exosomes in Michigan
Licensed Michigan practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Michigan buyers need their own professional license and NPI; the wholesale distributor license is the supplier’s obligation, not the purchaser’s.
Michigan’s wholesale regime is broader than most: the same Board of Pharmacy license reaches prescription devices as well as prescription drugs, and it applies to distributors whether or not they are located in the state. The state’s stem cell provision, by contrast, is a 2008 constitutional amendment about research, and it is worth knowing what that amendment covers and what it does not.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Michigan? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material; compounded preparations available through the 503A pharmacy partner |
| Last reviewed | 16 October 2026 |
Ordering from Michigan
ExaVeyra ships to licensed practices in all 50 states, Michigan included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Michigan professional license in good standing, verifiable through the Bureau of Professional Licensing’s MiPLUS license verification system.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Michigan sales and use tax exemption claim if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Michigan licenses wholesale distributors through the Board of Pharmacy within the Department of Licensing and Regulatory Affairs, with applications filed through the MiPLUS licensing system. MCL 333.17748 requires a pharmacy, manufacturer, wholesale distributor, or wholesale distributor-broker to hold the license whether or not it is located in Michigan, so a single license class covers in-state and out-of-state distributors alike. The rules extend the regime to prescription devices as well as prescription drugs, which most states’ permits do not, and each licensee designates a facility manager or pharmacist in charge who is jointly responsible for compliance. The license sits with the distributor, not with the purchasing practice.
MCL 333.17748; Mich. Admin. Code R. 338.561 to 338.565 · Michigan Board of Pharmacy, Bureau of Professional Licensing (LARA)
Michigan regenerative-medicine law
Michigan has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Michigan has no statute authorizing, conditioning, or requiring disclosure for unapproved regenerative therapy in a clinical setting, so federal law is the only layer that addresses it. What Michigan does have is Article I, Section 27 of its constitution, added by Proposal 2 in 2008 and effective 19 December 2008. That provision concerns embryonic stem cell research: it permits research allowed under federal law, limits how embryos may be sourced and used, and bars the sale of embryos. It authorizes no clinical service and places no conditions on any practice. Clinical practice in this area is governed by the Public Health Code, the boards that administer it, and federal law.
How this applies to exosomes
Michigan’s stem cell provision is a research amendment, not a practice law. Article I, Section 27 of the Michigan Constitution addresses how embryonic stem cell research may be conducted and says nothing about who may offer a regenerative product in a clinic, so there is no Michigan definition to read exosomes into or out of. Exosomes are acellular extracellular vesicles rather than stem cells in any case, and no state statute here reaches them. Exosome products in Michigan are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Michigan practice
Michigan is a delegation state, which is the practical thing to plan around. APRNs hold independent authority only over nonscheduled prescribing; everything else, including controlled substance prescribing and most procedures, traces back to a physician through delegation under MCL 333.16215 or a PA practice agreement under MCL 333.17047. All the relevant boards sit within the Bureau of Professional Licensing at LARA, so license verification runs through a single agency.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Michigan Board of Medicine may perform medical acts within their scope and are the source of any delegation. MCL 333.16215 lets a licensee delegate acts to qualified personnel under the licensee’s supervision, which is the mechanism most aesthetic delegation in Michigan runs through. |
| NP / APRN | Michigan recognizes the APRN as a specialty certification under the nursing license rather than an independent profession. Under 2016 PA 499, an APRN may prescribe nonscheduled prescription drugs in their own authority, but controlled substances in schedules 2 through 5 may be prescribed only as a delegated act of a physician with both names and both DEA registrations on the prescription (MCL 333.17211a). Other medical acts remain delegated acts, so an NP-led aesthetic practice in Michigan still operates under physician involvement. |
| PA | Physician assistants practice under a written practice agreement with a participating physician under MCL 333.17047, which must set the communication and decision-making process, designate an alternative physician for consultation, define the duties of both parties, and carry a 30-day termination provision. |
| RN | Registered nurses may perform delegated treatments within their license and under physician supervision pursuant to MCL 333.16215, after a prescriber has evaluated the patient and ordered the treatment. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Michigan expects a patient evaluation by a licensed prescriber, and an order, before a delegated treatment is administered; delegation under MCL 333.16215 presumes the delegating licensee has brought the patient within their supervision. Confirm current expectations with the Michigan Board of Medicine and the Michigan Board of Nursing, since this area is governed by the delegation statute and board interpretation rather than a single aesthetic-practice rule.
Ownership and clinic licensing
Michigan’s corporate practice position is statutory rather than a doctrine. MCL 450.1281 to 450.1285 require an entity providing services in a learned profession, medicine included, to organize as a professional corporation or PLLC, and every shareholder must be licensed in a professional service the entity provides. Non-licensed managers may run business operations through a management services organization but may not hold equity in the professional entity or influence clinical decisions. Structure this with Michigan counsel before opening.
Cold chain into Michigan
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Michigan order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Detroit | Wayne | Largest Michigan market, anchored by major hospital systems. |
| Troy | Oakland | Dense suburban med spa and dermatology corridor north of Detroit. |
| Grand Rapids | Kent | Largest west Michigan market with a growing aesthetic segment. |
| Ann Arbor | Washtenaw | Academic medical hub with research-adjacent practices. |
| Lansing | Ingham | Capital region market serving mid-Michigan. |
| Traverse City | Grand Traverse | Northern Michigan hub with seasonal resort demand. |
- Michigan orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every shipment arrives with the manufacturer’s handling instructions and the Certificate of Analysis for its lot.
Wholesale exosome supply by city in Michigan
Each city page covers local receiving conditions, delivery disruptions and business license rules for Michigan practices in that area.
Practice types we supply in Michigan
Michigan licensing and verification
Michigan Board of Medicine (LARA)
All Michigan health boards sit within one bureau, so verification runs through MiPLUS.
Michigan Board of Nursing (LARA)
Michigan Board of Pharmacy (LARA)
Licenses wholesale distributors and wholesale distributor-brokers for prescription drugs and devices.
Michigan Department of Treasury
Sales and use tax registration and exemption claims.
Michigan sourcing questions
- Does Michigan have a stem cell law?
- Not a practice law. Article I, Section 27 of the Michigan Constitution, added by Proposal 2 in 2008, is a research amendment: it permits embryonic stem cell research allowed under federal law and limits how embryos may be sourced. It authorizes no clinical service and places no conditions on any practice, so exosome products in Michigan are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Can a nurse practitioner run a practice in Michigan without a physician?
- Not in the way full-practice-authority states allow. Under 2016 PA 499 an APRN may prescribe nonscheduled prescription drugs in their own authority, but controlled substance prescribing and other medical acts remain delegated acts of a physician under MCL 333.17211a and MCL 333.16215. A Michigan aesthetic practice therefore plans around physician delegation and, in practice, a medical director.
- What does a Michigan physician assistant need in place?
- A written practice agreement with a participating physician under MCL 333.17047. The agreement sets the communication and decision-making process, designates an alternative physician for consultation, defines each party’s duties within their qualifications, carries a 30-day termination provision, and requires the participating physician to verify the PA’s credentials.
- Does my Michigan clinic need a wholesale distributor license to buy exosomes?
- No. The wholesale distributor license under MCL 333.17748 is held by the distributor shipping into Michigan, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA said so directly in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera exosome material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Michigan?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- MCL 333.17748, licensure of pharmacies, manufacturers, and wholesale distributors (accessed 16 October 2026)
- Michigan Constitution, Article I, Section 27 (Proposal 2 of 2008) (accessed 16 October 2026)
- MCL 333.17211a, APRN prescribing authority (accessed 16 October 2026)
- Michigan Board of Pharmacy (LARA) (accessed 16 October 2026)
- Michigan Board of Medicine (LARA) (accessed 16 October 2026)
- Michigan Department of Treasury (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: Defines the field’s current characterization and reporting standard for extracellular vesicles, the benchmark behind the COA and lot documentation this page describes.
- Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. Journal of Extracellular Vesicles, 2019. doi:10.1080/20013078.2019.1609206 PMID:31069028Consensus statementsupports: ISEV and ISCT position on what must be documented for an MSC-derived EV preparation, which is the documentation standard a buying practice should hold a supplier to.
- Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?. Cell Death and Disease, 2022. doi:10.1038/s41419-022-05034-x PMID:35787632Narrative reviewsupports: Reviews the preclinical state of MSC-EV research, including perinatal source material, which is why this page describes the field as investigational rather than established.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.